Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma
10.1038/leu.2011.53
Saved in:
Main Authors: | Chng, W.-J., Huang, G.F., Chung, T.H., Ng, S.B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P.L., Fonseca, R. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/110728 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network
by: Tan, D., et al.
Published: (2016) -
The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: An analysis of the Singapore multiple myeloma study group
by: Tan, D., et al.
Published: (2016) -
Investigating status of tumorigenic barriers in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM)
by: ZAHRA KABIRI
Published: (2010) -
Attenuation of STAT3 signaling cascade by daidzin can enhance the apoptotic potential of bortezomib against multiple myeloma
by: Yang, M.H., et al.
Published: (2021) -
Management of treatment-emergent peripheral neuropathy in multiple myeloma
by: Richardson, P.G., et al.
Published: (2016)